REFERENCES
- Adams L., Jeffrey F. P., Deboer B., Garas G. Ticlopidine-associated cholestatic hepatitis. Int. Med. J. 2002; 32: 359–360
- Alden C., Lin J., Smith P. Predictive toxicology technology for avoiding idiosyncratic liver injury. Preclinica May/June, 2003; 27–35
- Alvir J. M., Lieberman J. A. Agranulocytosis: Incidence and risk factors. J. Clin. Psychiatry 1994; 55(Suppl B)137–138, [PUBMED], [INFOTRIEVE]
- Andrade R. J., Lucena M. I., Martin-Vivaldi R., Fernandez M. C., Nogueras F., Pelaez G., Gomez-Outes A., Garcia-Escano M. D., Bellot V., Hervas A., Cardenas F., Bermudez F., Romero M., Sameron J. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J. Hepatol. 1999; 31: 641–646, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Arnold T. H, Jr, Epps J. M., 3rd, Cook H. R., Hamrick M. E. Dantrolene sodium: Urinary metabolites and hepatotoxicity. Res. Commun. Chem. Pathol. Pharmacol. 1983; 39: 381–398, [PUBMED], [INFOTRIEVE], [CSA]
- Asbury R. F., Rosenthal S. N., Descalzi M. E., Ratcliffe R. L., Arseneau J. C. Hepatic veno-occlusive disease due to DTIC. Cancer 1980; 45: 2670–2674, [PUBMED], [INFOTRIEVE]
- Askmark H., Wiholm B. Epidemiology of adverse reactions to carbamazepine as seen in a spontaneous reporting system. Acta Neurol. Scand. 1990; 81: 131–140, [PUBMED], [INFOTRIEVE]
- Ayrton A. D., Ioannides C., Parke D. V. Induction of the cytochrome P450 I and IV families and peroxisomal proliferation in the liver of rats treated with benoxaprofen. Possible implications in its hepatotoxicity. Biochem. Pharmacol. 1991; 42: 109–115, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Baillie T. A. Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem. Res. Toxicol. 1988; 1: 195–199, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ballet F. Hepatotoxicity in drug development: Detection, significance and solutions. J. Hepatol. 1997; 26(Suppl. 2)26–36, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bartle W. R., Fisher M. M., Kerenyi N. Disulfiram-induced hepatitis. Report of two cases and review of the literature. Dig. Dis. Sci. 1985; 50: 834–837, [CROSSREF]
- Baty V., Denis B., Goudot C., Bas V., Renkes P., Bigard M. A., Boissel P., Gaucher P. Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal. Gastroenterol. Clin. Biol. 1994; 18: 1129–1131, [PUBMED], [INFOTRIEVE], [CSA]
- Baud F., Bernuau J., Benmami N., Pariente E. A., Bouygues M., Guillan J., Roche-Sicot J., Degott C., Rueff B., Pessayre D., Benhamou J. P. Acute hepatitis caused by isaxonine phosphate (Nerfactor). Gastroenterol. Clin. Biol. 1983; 7: 352–354, [PUBMED], [INFOTRIEVE]
- Berson A., Descatoire V., Sutton A., Fau D., Maulny B., Vadrot N., Feldmann G., Berthon B., Tordjmann T., Pessayre D. Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: Role of mitochondrial permeability transition and metabolic activation. J. Pharmacol. Exp. Ther. 2001; 299: 793–800, [PUBMED], [INFOTRIEVE], [CSA]
- Berson A., Wolf C., Chachaty C., Fisch C., Fau D., Eugene D., Loeper J., Gauthier J. C., Beaune P., Pompon D., Maurel P., Pessayre D. Metabolic activation of the nitroaromatic antiandrogen flutamide by rat and human cytochrome P-450, including forms belonging to the 3A and 1A subfamilies. J. Pharmacol. Exp. Ther. 1993; 265: 366–372, [PUBMED], [INFOTRIEVE]
- Bertino J., Fish D. The safety profile of the fluoroquinolones. Clin. Ther. 2000; 22: 798–817, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bhogaraju A., Nazeer S., Al-Gaghdadi Y., Rahman M., Wrestler F., Patel N. Diclofenac-associated hepatitis. Southern Med. J. 1999; 92: 711–713, [CSA]
- Black M., Mitchell J. R., Zimmerman H. J., Ishak K. G., Epler G. R. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69: 289–302, [PUBMED], [INFOTRIEVE]
- Blum M. D., Graham D. J. Temafloxacin syndrome: Review of 95 cases. Clin. Infect. Dis. 1994; 18: 946–950, [PUBMED], [INFOTRIEVE], [CSA]
- Boelsterli U. A. Xenobiotic acyl glucuronides and acyl CoA thioesters as protein-reactive metabolites with the potential to cause idiosyncratic drug reactions. Curr. Drug Metab. 2002; 3: 439–450, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Boelsterli U. A., Zimmerman H. J., Kretz-Rommel A. Idiosyncratic liver toxicity of nonsteroidal anti-inflammatory drugs: Molecular mechanisms and pathology. Crit. Rev. Toxicol. 1995; 25: 207–235, [PUBMED], [INFOTRIEVE], [CSA]
- Bolt H. M., Remmer H. Implication of rifampicin-quinone in the irreversible binding of rifampicin to macromolecules. Xenobiotica 1976; 6: 21–32, [PUBMED], [INFOTRIEVE]
- Bolton J. L., Comeau E., Vukomanovic V. The influence of 4-alkylsubstituents on the formation and reactivit of 2-methoxy-quinone methides: Evidence that extended π-conjugation dramatically stabilized the quinone methide formed from eugenol. Chem.-Biol. Interact. 1995; 95: 279–290, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Bonierbale E., Valadon P., Pons C., Desfosses B., Dansette P. M., Mansuy D. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effect of the two compounds. Chem. Res. Toxicol. 1999; 12: 286–296, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bonkovsky H. L., Azar R., Bird S., Szabo G., Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: Risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. Sci. 2002; 47: 1632–1637, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Bourdi M., Larrey D., Nataf J., Bernuau J., Pessayre D., Iwasaki M., Guengerich F. P., Beaune P. H. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J. Clin. Invest. 1990; 85: 1967–1973, [PUBMED], [INFOTRIEVE], [CSA]
- Bourdi M., Tinel M., Beaune P. H., Pessayre D. Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. 1994; 45: 1287–1295, [PUBMED], [INFOTRIEVE], [CSA]
- Breyer-Pfaff U., Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J. Pharm. Pharmacol. 2004; 56: 1601–1606, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Buchweitz J. P., Ganey P. E., Bursian S. J., Roth R. A. Underlying endotoxemia augments toxic responses to chlorpromazine: Is there a relationship to drug idiosyncrasy?. J. Pharmacol. Exp. Ther. 2002; 300: 460–467, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Caldwell J., Fakurazi S., Ramsay L. A., Somchit N., Goldin R. D. Benoxaprofen forms protein adducts in the bile canaliculi of female CD1 mice. Toxicol. Sci. 2000; 54(Suppl. 1), 46 (Abstract)
- Castillo J. R., Torello J., Hernandez A. Liver injury caused by ebrotidine: A new example of the utility of the postmarketing surveillance. Eur. J. Clin. Pharmacol. 2000; 56: 187–189, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Castillo M., Smith P. C. Disposition and reactivity of ibuprofen and ibufenac acyl glucuronides in vivo in the rhesus monkey and in vitro with human serum albumin. Drug Metab. Dispos. 1995; 23: 566–572, [PUBMED], [INFOTRIEVE], [CSA]
- Cattelan A. M., Erne E., Salatino A., Trevenzoli M., Carretta G., Meneghetti F., Cadrobbi P. Severe hepatic failure related to nevirapine treatment. Clin. Infect. Dis. 1999; 29: 455–456, [PUBMED], [INFOTRIEVE], [CSA]
- Chase R. E., Holaday D. A., Fiserove-Bergerova V., Saidman L. J., Mack F. E. The biotransformation of ethrane in man. Anesthesiology 1971; 35: 262–267, [PUBMED], [INFOTRIEVE]
- Christie G., Breckenridge A. M., Park B. K. Drug-protein conjugates–XVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem. Pharmacol. 1989; 38: 1451–1458, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Clark J. A., Zimmerman H. J., Tanner L. A. Labetolol hepatotoxicity. Ann. Intern. Med. 1990; 113: 210–213, [PUBMED], [INFOTRIEVE], [CSA]
- Cohen E. N., Trudell J. R., Edwards H. D., Watson D. Urinary metabolites of halothane in man. Anesthesiology 1975; 43: 392–401, [PUBMED], [INFOTRIEVE]
- Cooper R. G., Evans D. A.P., Whibley E. J. Polymorphic hydroxylation of perhexiline maleate in man. J. Med. Genet. 1984; 21: 27–33, [PUBMED], [INFOTRIEVE], [CSA]
- Cui L., Yoon S., Schinazi R. F., Sommadossi J.-P. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells. J. Clin. Invest. 1995; 95: 555–563, [PUBMED], [INFOTRIEVE], [CSA]
- Cuthbert M. F. Adverse reactions to non-steroidal antirheumatic drugs. Curr. Med. Res. Opin. 1974; 2: 600–610, [PUBMED], [INFOTRIEVE]
- Cutrin P. C., Nieto P. E., Batalla E. A., Casal I. L., Perez B. E., Lorenzo Zuniga V. Toxic hepatitis from cinchophen: Report of 3 cases. Med Clin (Barc) 1991; 97: 104–106
- Dahlin D. C., Nelson S. D. Synthesis, decomposition kinetics, and preliminary toxicological studies of pure N-acetyl-p-benzoquinone imine, a proposed toxic metabolite of acetaminophen. J. Med. Chem. 1982; 25: 885–886, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Dahms M., Spahn-Langguth H. Covalent binding of acidic drugs via reactive metabolites: Detection of benoxaprofen and flunoxaprofen protein adducts in biological material. Pharmazie 1996; 51: 874–881, [PUBMED], [INFOTRIEVE]
- Danan G., Homberg J. C., Bernuau J., Roche-Sicot J., Pessayre D. Iproniazid-induced hepatitis. The diagnostic value of a new antimitochondrial antibody anti-M6. Gastroenterol. Clin. Biol. 1983; 7: 529–532, [PUBMED], [INFOTRIEVE]
- Dasaradhi L., Shibutami S. Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 1997; 10: 189–196, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dehal S. S., Kupfer D. Evidence that the catechol 3,4-dihydroxytamoxifen is a proximate intermediate to the reactive species binding covalently to proteins. Cancer Res. 1996; 56: 1283–1290, [PUBMED], [INFOTRIEVE]
- Dehal S. S., Kupfer D. Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: Involvement of catechols in covalent binding to hepatic proteins. Drug Metab. Dispos. 1999; 27: 681–688, [PUBMED], [INFOTRIEVE], [CSA]
- Depla A. C., Vermeersch P. H., van Gorp L. H., Nadorp J. H. Fatal acute liver failure associated with pirprofen. Report of a case and review of the literature. Neth. J. Med. 1990; 37: 23–36
- Dieckhaus C. M., Miller T. A., Sofia R. D., Macdonald T. L. A mechanistic approach to understanding species differences in felbamate bioactivation: Relevance to drug-induced idiosyncratic reactions. Drug Metab. Dispos. 2000; 28: 814–822, [PUBMED], [INFOTRIEVE], [CSA]
- Dieckhaus C. M., Santos W. L., Sofia R. D., Macdonald T. L. The chemistry, toxicology, and identification in rat and human urine of 4-hydroxy-5-phenyl-1,3-oxazaperhydroin-2-one: A reactive metabolite in felbamate bioactivation. Chem. Res. Toxicol. 2001; 14: 958–964, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Dieckhaus C. M., Thompson C. D., Roller S. G., Macdonald T. L. Mechanisms of idiosyncratic drug reactions: The case of felbamate. Chem.-Biol. Interact. 2002; 142: 99–117, [PUBMED], [INFOTRIEVE], [CSA]
- Dreifuss F. E., Santilli N., Langer D. H., Sweeney K. P., Moline K. A., Menander K. B. Valproic acid hepatic fatalities: A retrospective review. Neurology 1987; 37: 379–385, [PUBMED], [INFOTRIEVE]
- Durand A., Thenot J. P., Bianchetti G., Morselli P. L. Comparative pharmacokinetic profile of two imidazopyridine drugs: Zolpidem and alpidem. Drug Metab. Rev. 1992; 24: 239–266, [PUBMED], [INFOTRIEVE]
- Durham J. A., Gandolfi A. J., Bentley J. B. Hepatotoxicological evaluation of dantrolene sodium. Drug Chem. Toxicol. 1984; 7: 23–40, [PUBMED], [INFOTRIEVE], [CSA]
- Dybing E., Nelson S. D., Mitchell J. R., Sasame H. A., Gillette J. R. Oxidation of α -methyldopa and other catechols by cytochrome p-450-generated superoxide anion: Possible mechanism of methyldopa hepatitis. Mol. Pharmacol. 1976; 12: 911–920, [PUBMED], [INFOTRIEVE]
- Egger H., Bartlett F., Yuan H. P., Karliner J. Metabolism of pirprofen in man, monkey, rat and mouse. Drug Metab. Dispos. 1982; 10: 529–536, [PUBMED], [INFOTRIEVE]
- Eliasson E., Stal P., Oksanen A., Lytton S. Expression of autoantibodies to specific cytochromes p450 in a case of disulfiram hepatitis. J. Hepatol. 1998; 29: 819–825, [PUBMED], [INFOTRIEVE], [CROSSREF]
- EMEA (European Medicines Evaluation Agency). 2000, Committee for Proprietary Medicinal Products (CPMP/1694/99), Scientific Discussion, accessed at www.eudra.org/humandocs/PDFs/EPAR/Arava/169499en6%20.pdf
- Erve J. C.L., Jensen O. N., Valentine H. S., Amarnath V., Valentine W. M. Disulfiram generates a stable N,N-diethylcarbamoyl adduct on Cys-125 of rat hemoglobin β-chains in vivo. Chem. Res. Toxicol. 2000; 13: 237–244, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Evans D. C., Watt A. P., Nicoll-Griffith D. A., Baillie T. A. Drug-protein adducts: An industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 2004; 17: 3–16, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fattinger K., Funk C., Pantze M., Weber C., Reichen J., Stieger B., Meier P. J. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 2001; 69: 223–231, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Fau D., Eugene E., Berson A., Letteron P., Fromenty B., Fisch C., Pessayre D. Toxicity of the antiandrogen flutamide in isolated rat hepatocytes. J. Pharmacol. Exp. Ther. 1994; 269: 954–962, [PUBMED], [INFOTRIEVE], [CSA]
- Fernandes N. F., Geller S. A., Fong T.-L. Terbinafine hepatotoxicity: Case report and review of the literature. Am J Gastroenterology 1998; 93: 459–460
- Fichtenbaum C. J., Gerber J. G. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin. Pharmacokinet 2002; 41: 1195–1211, [PUBMED], [INFOTRIEVE], [CSA]
- Fouin-Fortunet H., Letteron P., Tinel M., Degott C., Flejou J. F., Pessayre D. Mechanism for isaxonine hepatitis. II. Protective role of glutathione and toxicological studies in mice. J. Pharmacol. Exp. Ther. 1984; 229: 851–858, [PUBMED], [INFOTRIEVE]
- Friedman M. A., Woodcock J., Lumpkin M. M., Shuren J. E., Hass A. E., Thompson L. J. The safety of newly approved medicines: Do recent market removals mean there is a problem?. JAMA 1999; 281: 1728–1734, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharm. Ther. 1995; 67: 101–154, [CROSSREF], [CSA]
- Fung M., Thornton A., Mybeck K., Wu J. H., Hornbuckle K., Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets—1960 to 1999. Drug Information J. 2001; 35: 293–317
- Furst S. M., Uetrecht J. P. Carbamazepine metabolism to a reactive intermediate by the myeloperoxidase system of activated neutrophils. Biochem Pharmacol. 1993; 45: 1267–1275, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gale E. A. Lessons from the glitazones: A story of drug development. Lancet 2001; 357: 1870–1875, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gandolfi A. H., White R. D., Sipes I. G., Pohl L. R. Bioactivation and covalent binding of halothane in vitro. Studies with [3H] and [14C] halothane. J. Pharmacol. Exp. Ther. 1980; 214: 721–727, [PUBMED], [INFOTRIEVE]
- Ganey P. E., Roth R. A. Concurrent inflammation as a determinant of susceptibility to toxicity from xenobiotic agents. Toxicology 2001; 28: 195–208, [CROSSREF]
- Garcia-Pando A. C., Garcia del Pozo J., Sanchez A. S., Martin A. V., Rueda de Castro A. M., Lucena M. I. Hepatotoxicity associated with the new antidepressants. J. Clin. Psychiatry 2002; 63: 135–137
- Gardner I., Leeder J. S., Chin T., Zahid N., Uetrecht J. P. A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo. Mol. Pharmacol. 1998; 53: 999–1008, [PUBMED], [INFOTRIEVE], [CSA]
- Gasbarrini G., Gentiloni N., Febbraro S., Gasbarrini A., Di Campli C., Cesana M., Migio F., Miglioli M., Ghinelli F., D'Ambrosi A., Amoroso P., Pacini F., Salvadori G. Acute liver injury related to the use of niperotidine. J. Hepatol. 1997; 27: 583–586, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Gascoigne E. W., Barton G. J., Michales M., Meuldermans W., Heykants J. The kinetics of ketoconazole in animals and man. Clin. Res. Rev. 1981; 1: 177–187
- Gavish D., Katz M., Gottehrer N., Israeli A., Lijovetzky G., Holubar K. Cholestatic jaundice, an unusual side effect of etretinate. J. Am. Acad. Dermatol. 1985; 13: 669–670, [PUBMED], [INFOTRIEVE]
- Genéve J. Inhibition of mitochondrial beta-oxidation of fatty acids by pirprofen. Role in microvesicular steatosis due to this non-steroidal anti-inflammatory drug. J. Pharmacol. Exp. Ther. 1987; 242: 1137–1142
- Genéve J., Larrey D., Amouyal G., Belghiti J., Pessayre D. Metabolic activation of the tricyclic antidepressant amineptine by human liver cytochrome p-450. Biochem. Pharmacol. 1987; 36: 2421–2424, [CROSSREF]
- Giles F. J., Kantarjian H. M., Kornblau S. M., Thomas D. A., Garcia-Manero G., Waddelow T. A., David C. L., Phan A. T., Colburn D. E., Rashid A., Estey E. H. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92: 406–413, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Goodwin D. C., Aust S. D., Grover T. A. Free radicals produced during the oxidation of hydrazines by hypochlorous acid. Chem. Res. Toxicol. 1996; 9: 1333–1339, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Haasio K., Sopanen L., Vaalavirta L., Linden I.-B., Heinonen E. F. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J. Neural Transm. 2001; 108: 79–91, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Haasio K., Koponen A., Penttila K. E., Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. Eur. J. Pharmacol. 2002; 453: 21–26, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ha-Duong N. T., Dijols S., Macherey A. C., Goldstein J. A., Dansette P. M., Mansuy D. Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19. Biochemistry 2001; 40: 12112–12122, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hard G. C., Iatropoulos M. J., Jordan K., Radi L., Kaltenberg O. P., Imondi A. R., Williams G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res. 1993; 53(19)4534–4541, [PUBMED], [INFOTRIEVE]
- Hargus S. J., Amouzedeh H. R., Pumford N. R., Myers T. G., McCoy S. C., Pohl L. R. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 1994; 7: 575–582, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Harrison A. C., Kitteringham N. R., Clarke J. B., Park B. K. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem. Pharmacol. 1992; 43: 1421–1430, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Hart B. W., Faiman M. D. In vitro and in vivo inhibition of rat liver aldehyde dehydrogenase by S-methyl N,N-diethylthiocarbamate sulfoxide, a new metabolite of disulfiram. Biochem. Pharmacol. 1992; 43: 403–406, [PUBMED], [INFOTRIEVE], [CROSSREF]
- He K., Woolf T. F., Kindt E. K., Fielder A. E., Talaat R. E. Troglitazone quinone formation catalyzed by human and rat CYP3A: An atypical CYP oxidation reaction. Biochem. Pharmacol. 2001; 62: 191–198, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: A review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 1982; 23: 1–36, [PUBMED], [INFOTRIEVE]
- Hendrickson H. P., Scott D. O., Lunte C. E. Identification of 9-hydroxylamine-1,2,3,4-tetrahydroacridine as a hepatic microsomal metabolite of tacrine by high-performance liquid chromatography and electrochemistry. J. Chromatogr. 1989; 487: 401–408, [PUBMED], [INFOTRIEVE]
- Hill D. L. Microsomal metabolism of triazenyl-imidazoles. Cancer Res. 1975; 35: 3106–3110, [PUBMED], [INFOTRIEVE]
- Holaday D. A., Fiserova-Bergerova V., Latto I. P., Zumbiel M. A. Resistance of isoflurane to biotransformation in man. Anesthesiology 1975; 43: 392–401
- Homberg J. C., Stelly N., Andreis I., Abuaf N., Sadoun F., Andre J. A new antimitochondria antibody (anti-M6) in iproniazid-induced hepatitis. Clin. Exp. Immunol. 1982; 47: 93–102, [PUBMED], [INFOTRIEVE]
- Homberg J. C., Andre C., Abuaf N. A new anti-liver kidney microsome antibody (anti-KLM2) in tienilic acid-induced hepatitis. Clin. Exp. Immunol. 1984; 55: 561–570, [PUBMED], [INFOTRIEVE], [CSA]
- Hueper W. E. Cinchophen (Atophan): A critical review. Medicine 1948; 27: 43
- Hummer M., Kurz M., Kurzthaler I., Oberbauer H., Miller C., Fleischhacker W. W. Hepatotoxicity of clozapine. J. Clin. Psychopharmacol. 1997; 17(4)314–317, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Iverson S. L., Uetrecht J. P. Identification of a reactive metabolite of terbinafine: Insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol. 2001; 14: 175–181, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jarman M., Poon G. K., Rowlands M. G., Grimshaw R. M., Horton M. N., Potter G. A., McCague R. The deuterium isotope effect for the α-hydroxylation of tamoxifen by rat liver microsomes accounts for the reduced genotoxicity of D5-ethyltamoxifen. Carcinogenesis 1995; 16: 683–688, [PUBMED], [INFOTRIEVE], [CSA]
- Jayyosi Z., Totis M., Souhaili H., Goulon-Ginet C., Livertous M. H., Batt A. M., Siest G. Induction of hepatic cytochrome P-450c-dependent monooxygenase activities by dantrolene in rat. Biochem. Pharmacol. 1987; 36: 2481–2487, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jayyosi Z., Villoutreix J., Ziegler J. M., Batt A. M., De Maack F., Siest G., Thomas P. E. Identification of cytochrome P-450 isozymes involved in the hydroxylation of dantrolene by rat liver microsomes. Drug Metab. Dispos. 1993; 21: 939–945, [PUBMED], [INFOTRIEVE], [CSA]
- Jean P., Lopez-Garcia P., Dansette P., Mansuy D., Goldstein J. L. Oxidation of tienilic acid by human yeast-expressed cytochrome P-450 2C8, 2C9, 2C18 and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9. Eur. J. Biochem. 1996; 241: 797–804, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jiang X., Khursigara G., Rubin R. L. Transformation of lupus-inducing drugs to cytotoxic products by activated neutrophils. Science 1994; 266: 801–813
- Jin L., Davis M. G., Hu P., Baillie T. A. Identification of novel glutathione conjugates of disulfiram and diethyldithiocarbamate in rat bile by liquid chromatography-tandem mass spectrometry. Evidence for metabolic activation of disulfiram in vivo. Chem. Res. Toxicol. 1994; 7: 526–533, [PUBMED], [INFOTRIEVE], [CSA]
- Johnson S., Baraboutis J. G., Sha B. E., Proia L. A., Kessler H. A. Adverse effects associated with use of nevirapine in HIV postexposure for 2 health care workers [Letters]. JAMA 2000; 284: 2722–2723, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Jones R. M., Lim C. K. Toremifene metabolism in rat, mouse and human liver microsomes: Identification of α-hydroxytoremifene by LC-MS. Biomed. Chromatogr. 2002; 16: 361–363, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Jorga K., Fotteler B., Heizmann P., Gasser R. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br. J. Clin. Pharmacol. 1999; 48: 513–520, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Joshi E. M., Heasley B. H., Chordia M. D., Macdonald T. L. In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatoxicity. Chem. Res. Toxicol. 2004; 17: 137–143, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ju C., Uetrecht J. P. Detection of 2-hydroxyiminostilbene in the urine of patients taking carbamazepine and its oxidation to a reactive iminoquinone intermediate. J. Pharmacol. Exp. Ther. 1999; 288: 51–56, [PUBMED], [INFOTRIEVE], [CSA]
- Ju C., Uetrecht J. P. Mechanism of idiosyncratic drug reactions: Reactive metabolite formation, protein binding and the regulation of the immune system. Curr. Drug Metab. 2002; 3: 367–377, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kalgutkar A. S., Vaz A. D.N., Lame M. E., Henne K. R., Soglia J., Zhao S. X., Abramov Y. A., Lombardo F., Collin C., Hendsch Z., Hop C. E.C.A. Bioactivation of the nontricyclic antidepressant nefazodone to a reactive quinone-imine species in human liver microsomes and recombinant cytochrome P450 3A4. Drug Metab. Dispos. 2005; 33: 243–253, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kapetanovic I. M., Torchin C. D., Strong J. M., Ynoekawa W. D., Lu C., Li A. P., Dieckhaus C. M., Santos W. L., Macdonald T. L., Sofia R. D., Kupferberg H. J. Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro. Chem. Biol. Interact. 2002; 142: 119–134, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kassahun K., Hu P., Grillo M. P., Davis M. R., Jin L., Baillie T. A. Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A-dependent and -independent processes. Chem. Biol. Interact. 1994; 90: 253–275, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kassahun K., Pearson P. G., Tang W., McIntosh I., Leung K., Elmore C., Dean D., Wang R., Doss G., Baillie T. A. Studies on the metabolism of troglitazone to reactive metabolites in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 2001; 14: 62–70, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kenna J. G., Satoh H., Christ D. D., Pohl L. R. Metabolic basis for a drug hypersensitivity: Antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 1988; 245: 1103–1109, [PUBMED], [INFOTRIEVE]
- King C., Tang W., Ngui J., Tephly T., Braun M. Characterization of rat and human UDP-glucuronosyl-transferases responsible for the in vitro glucuronidation of diclofenac. Toxicol. Sci. 2001; 61: 49–53, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kirkman S. K., Zhang M. M.-Y., Horwatt P. M., Scatine J. Isolation and identification of bromfenac glucoside from rat bile. Drug Metab. Dispos. 1998; 26: 720–723, [PUBMED], [INFOTRIEVE], [CSA]
- Knights K. M., Cassidy M. R., Drew R. Benoxaprofen induced toxicity in isolated rat hepatocytes. Toxicology 1986; 40: 327–339, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Knights K. M., Gasser R., Klemisch W. In vitro metabolism of acitretin by human liver microsomes: Evidence of an acitretinoyl-coenzyme A thioester conjugate in the transesterification to etretinate. Biochem. Pharmacol. 2000; 60: 507–516, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Koenigs L. L., Peter R. M., Hunter A. P., Haining R. L., Rettie A. E., Friedberg T., Pritchard M. P., Shor M., Rushmore T. H., Trager W. F. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9. Biochemistry. 1999; 38: 2312–2319, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kreiss C., Amin S., Nalesnik M. A., Chopra K., Shakil A. O. Severe cholestatic hepatitis in a patient taking acitretin. Am. J. Gastroenterol. 2002; 97: 775–777, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kretz-Rommel A., Boelsterli U. A. Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol. Appl. Pharmacol. 1993; 120: 155–161, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Kretz-Rommel A., Boelsterli U. A. Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: Radiochemical and immunochemical analysis. Mol. Pharmacol. 1994a; 45: 237–244, [PUBMED], [INFOTRIEVE], [CSA]
- Kretz-Rommel A., Boelsterli U. A. Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins: Retention of the glucuronic acid moiety in the adduct. Drug Metab. Dispos. 1994b; 22: 956–961, [PUBMED], [INFOTRIEVE], [CSA]
- Lake-Bakaar G., Scheuer P. J., Sherlock S. Hepatic reactions associated with ketoconazole in the United Kingdom. Br. Med. J. 1987; 294: 419–422
- Lasser K. E., Allen P. D., Woolhandler S. J., Himmelstein D. U., Wolfe S. M., Bor D. H. Timing of new black box warnings and withdrawals for prescription medications. JAMA 2002; 287: 2215–2220, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lazaros G. A., Stavrinos C., Papatheodoridis G. V., Delladetsima J. K., Toliopoulos A., Tasopoulos N. C. Amineptine induced liver injury. Report of two cases and brief review of the literature. Hepato-Gastroenterology 1996; 43: 1015–1019, [PUBMED], [INFOTRIEVE], [CSA]
- Lazarou J., Pomeranz B. H., Corey B. N. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies. JAMA 1998; 279: 1200–1205, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lecoeur S., Andre C., Beaune P. H. Tienilic acid-induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 1996; 50: 326–333, [PUBMED], [INFOTRIEVE], [CSA]
- Lertratanangkoon K., Horning M. G. Metabolism of carbamazepine. Drug Metab. Dispos. 1982; 10: 1–10, [PUBMED], [INFOTRIEVE]
- Letteron P., Descatoire V., Tinel M., Maurel P., Labbe G., Loeper J., Larrey D., Freneaux E., Pessayre D. Metabolic activation of the antidepressant tianeptine. I. Cytochrome p-450-mediated in vitro covalent binding. Biochem. Pharmacol. 1989; 38: 3241–3246, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Letteron P., Fouin-Fortunet H., Tinel M., Danan G., Belghiti J., Pessayre D. Mechanism for isaxonine hepatitis. I. Metabolic activation by mouse and human cytochrome P-450. J. Pharmacol. Exp. Ther. 1984; 229: 845–850, [PUBMED], [INFOTRIEVE], [CSA]
- Lewis W., Levine E. S., Griniuviene B., Tankersley K. O., Colacino J. M., Sommadossi J.-P., Watanabe K. A., Perrino F. W. Fialuridine and its metabolites inhibit DNA polymerase γ at sites multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc. Natl. Acad. Sci. USA. 1996; 93: 3592–3597, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Li A. P. A review of the common properties of drugs with idiosyncratic hepatotoxicity and the “multiple determinant hypothesis” for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. 2002; 142: 7–23, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Li A. P., Reith M. K., Rasmussen A., Gorski J. C., Hall S. D., Xu L., Kaminski D. L., Cheng L. K. Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: Evaluation of rifampin, rifapentine and rifabutin. Chem. Biol. Interact. 1997; 107: 17–30, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Li X. Q., Bjorkman A., Andersson T. B., Ridderstrom M., Masimirembwa C. M. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzyme-specific probe substrate. J. Pharmacol. Exp. Ther. 2002; 300: 399–407, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lind R. C., Gandolfi A. J., Sipes I. G., Brown B. R. The involvement of endotoxin in halothane-associated liver injury. Anesthesiology 1984; 61: 544–550, [PUBMED], [INFOTRIEVE], [CSA]
- Lipsky J. J., Shen M. L., Naylor S. Overview—In vitro inhibition of aldehyde dehydrogenase by disulfiram and metabolites. Chem. Biol. Interact. 2001; 130–132: 81–91, [CROSSREF]
- Liu Z. C., Uetrecht J. P. Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells. J. Pharmacol. Exp. Ther. 1995; 275: 1476–1483, [PUBMED], [INFOTRIEVE], [CSA]
- Lloyd S., Hayden M. J., Sakai Y., Fackett A., Silber P. M., Hewitt N. J., Li A. P. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Chem. Biol. Interact. 2002; 142: 57–71, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lopez-Garcia M. P., Dansette P. M., Mansuy D. Thiophene derivatives as new mechanism-based inhibitors of cytochromes P-450: Inactivation of yeast-expressed human liver cytochrome P-450 2C9 by tienilic acid. Biochemistry 1994; 33: 166–175, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Lopez-Larraza D. M., Moore K., Jr., Dedon P. C. Thiols alter the partitioning of calicheamicin-induced deoxyribose 4′-oxidation reactions in the absence of DNA radical repair. Chem. Res. Toxicol. 2001; 14: 528–535, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Lucena M. I., Andrade R. J., Rodrigo L., Salmeron J., Alvarez A., Lopez-Garrido M. J., Camargo R., Alcantara R. Trovafloxacin-induced acute hepatitis. Clin. Infect. Dis. 2000; 30: 400–401, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Luyendyk J. P., Maddox J. F., Cosma G. N., Ganey P. E., Cockerell G. L., Roth R. A. Ranitidine treatment during a modest inflammatory response precipitates idiosyncrasy-like liver injury in rats. J. Pharmacol. Exp. Ther. 2003; 307: 1227–1234, [CROSSREF], [CSA]
- Macfarlane B., Davies S., Mannan K., Sarsam R., Pariente D., Dooley J. Fatal acute fulminant liver failure due to clozapine: A case report and review of clozapine-induced hepatotoxicity. Gastroenterology 1997; 112: 1707–1709, [PUBMED], [INFOTRIEVE], [CSA]
- Madan A., Parkinson A., Faiman M. D. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: Role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin. Exp. Res. 1998; 22: 1212–1219, [PUBMED], [INFOTRIEVE], [CSA]
- Madden S., Woolf T. F., Pool W. F., Park B. K. An investigation into the formation of stable, protein-reactive and cytotoxic metabolites from tacrine in vitro. Biochem. Pharmacol. 1993; 46: 13–20, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Madden S., Spaldin V., Hayes R. N., Woolf T. F., Pool W. F., Park B. K. Species variation in the bioactivation of tacrine by hepatic microsomes. Xenobiotica 1995; 25: 103–116, [PUBMED], [INFOTRIEVE], [CSA]
- Maggs J. L., Williams D., Pirmohamed M., Park B. K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 1995; 275: 1463–1475, [PUBMED], [INFOTRIEVE], [CSA]
- Mani C., Kupfer D. Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: Possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res. 1991; 51: 6052–6058, [PUBMED], [INFOTRIEVE]
- Martinat C., Amar C., Dansette P. M., Leclaire J., Lopez-Garcia P., Cao T. D., N'Guyen H. N., Mansuy D. In vitro metabolism of isaxonine phosphate: Formation of two metabolites, 5-hydroxyisaxonine and 2-aminopyrimidine, and covalent binding to microsomal proteins. Eur. J. Pharmacol. 1992; 228: 63–71, [PUBMED], [INFOTRIEVE]
- Masubuchi Y., Horie T. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol. 1999; 12: 1028–1032, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Masubuchi Y., Nakano T., Ose A., Horie T. Differential selectivity in carbamazepin-induced inactivation of cytochrome p450 enzymes in rat and human liver. Arch. Toxicol. 2001; 75: 538–543, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Matzinger P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 1994; 12: 991–1045, [PUBMED], [INFOTRIEVE], [CSA]
- Mays D. C., Nelson A. N., Fauq A. H., Shriver Z. H., Veverka K. A., Naylor S., Lipsky J. J. S-Methyl N,N-diethylthiocarbamate sulfone, a potential metabolite of disulfiram and potent inhibitor of low Km mitochondrial aldehyde dehydrogenase. Biochem. Pharmacol. 1995; 49: 693–700, [PUBMED], [INFOTRIEVE], [CSA]
- Mays D. C., Ortiz-Bermudez P., Lam J. P., Tong I. H., Fauq A. H., Lipsky J. J. Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem. Pharmacol. 1998; 55: 1099–1103, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- McKenzie R., Fried M. W., Sallie R., Conjeevaram H., Di Bisceglie A. M., Park Y., Savarese B., Kleiner D., Tsokos M., Luciano C., Pruett T., Stotka J. L., Straus S. E., Hoofnagle J. H. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 1995; 333: 1099–1105, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Menor J. A., Dunham D. B., Leflunomide. A new agent for the treatment of rheumatoid arthritis. J. Pharm. Soc. Wisc. Sept./Oct., 1999; 33–38, [CSA]
- Mitchell J. E., Morley J. E., Levine A. S., Hatsukami D., Gannon M., Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol. Psychiatry 1987; 22: 35–42, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Morgan M. Y., Reshef R., Shah R. R., Oates N. S., Smith R. I., Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984; 25: 1057–1064, [PUBMED], [INFOTRIEVE]
- Nelson S. D., Mitchell J. R., Snodgrass W. R., Timbrell J. A. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J. Pharmacol. Exp. Ther. 1976a; 206: 574–585
- Nelson S. D., Mitchell J. R., Timbrell J. A., Snodgrass W. R., Corcoran G. B. Isoniazid and iproniazid: Activation of metabolites to toxic intermediates in man and rat. Science 1976b; 193: 901–903, [PUBMED], [INFOTRIEVE]
- Nelson S. D., Mitchell J. R., Snodgrass W. R., Timbrell J. A. Hepatotoxicity and metabolism of iproniazid and isopropylhydrazine. J. Pharmacol. Exp. Ther. 1978; 206: 574–585, [PUBMED], [INFOTRIEVE]
- Neuberger J., Kenna J. G., Nouri A. K., Williams R. Antibody mediated hepatocyte injury in methyldopa induced hepatotoxicity. Gut 1985; 26: 1233–1239, [PUBMED], [INFOTRIEVE]
- Nissinen E., Kaheinen P., Penttila K. E., Kaivola J., Linden I.-B. Entacapone, a novel catechol-O-methyl transferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production. Eur. J. Pharmacol. 1997; 340: 287–294, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Njoku D., Laster M. J., Gong D. H., Eger E. I., II, Reed G. F., Martin J. L. Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury. Anesth. Analg. 1997; 84: 173–178, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Osman M., Chandrasekaran A., Chan K., Scatina J., Ermer J., Cevallos W., Sisenwine S. F. Metabolic disposition of 14C-bromfenac in healthy male volunteers. J. Clin. Pharmacol. 1998; 38: 744–752, [PUBMED], [INFOTRIEVE], [CSA]
- Paliard P., Vitrey D., Fournier G., Belhadjali J., Patricot L., Berger F. Perhexiline maleate-induced hepatitis. Digestion 1978; 17: 419–427, [PUBMED], [INFOTRIEVE]
- Palmer W. L., Woodall P. S. Cinchophen—Is there a safe method of administration?. J. Amer. Med. Assoc. 1936; 107: 760–764
- Pariente E. A., Pessayre D., Bernuau J., Degott C., Benhamou J. P. Dihydralazine hepatitis: Report of a case and review of the literature. Digestion 1983; 27: 47–52, [PUBMED], [INFOTRIEVE]
- Park B. K., Pirmohamed M., Kitteringham N. R. Role of drug disposition in drug hypersensitivity: A chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 1998; 11: 969–988, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Park B. K., Kitteringham N. R., Powell H., Pirmohamed M. Advances in molecular toxicology—Towards understanding idiosyncratic drug toxicity. Toxicology 2000; 153: 39–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Paschke R., Heine M., Braun S., Usadel K. H. Mechanisms of hepatotoxicity caused by dacarbazine in rats. J. Cancer Res. Clin. Oncol. 1993; 119: 475–481, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pellock J. M. Pelbamate. Epilepsia 1999; 40(Suppl. 5)S57–S62, [PUBMED], [INFOTRIEVE]
- Pessayre D., Bichara M., Feldmann G., Degott C., Potet F., Benhamou J.-P. Perhexiline maleate-induced cirrhosis. Gastroenterology 1979; 76: 170–177, [PUBMED], [INFOTRIEVE]
- Pfohl D. N., Allen J. I., Atkinson R. L., Knopman D. S., Malcolm R. J., Mitchell J. E., Morley J. E. Naltrexone hydrochloride (Trexan): A review of serum transaminase elevations at high dosage. NIDA Res. Monogr. 1986; 67: 66–72, [PUBMED], [INFOTRIEVE]
- Pirmohamed M., Kitteringham N. R., Guenthner T. M., Breckenridge A. M., Park B. K. An investigation of the formation of cytotoxic, protein-reactive and stable metabolites from carbamazepine in vitro. Biochem. Pharmacol. 1992; 43: 1675–1682, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pirmohamed M., Park B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 2001; 22: 298–305, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pons C., Dansette P. M., Gregeois J., Homberg J. C., Billett E. E., Mansuy D. Human anti-mitochondria autoantibodies appearing in iproniazid-induced immunoallergic hepatitis recognize human liver monoamine oxidase B. Biochem. Biophys. Res. Commun. 1996; 218: 118–124, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Poon G. K., Chen Q., Teffera Y., Ngui J. S., Griffin P. R., Braun M. P., Doss G. A., Freeden C., Stearns R. A., Evans D. C., Baillie T. A., Tang W. Bioactivation of diclofenac intermediates- identification of urinary mercapturic acid derivatives in rats and humans. Drug Metab. Dispos. 2001; 29: 1608–1612, [PUBMED], [INFOTRIEVE], [CSA]
- Pottier J., Busigny M., Raynaud J. P. Biotransformations of glafenine in the rat and in man. Eur. J. Drug Metab. Pharmacokinet. 1979; 4: 109–115, [PUBMED], [INFOTRIEVE]
- Prakash M., Poreddy V., Tiyyagura L., Bonacini M. Jaundice and hepatocellular damage associated with nevirapine therapy. Am. J. Gastroenterol. 2001; 96: 1571–1574, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Pumford N. R, Myers T. G., Davila J. C., Highet R. J., Pohl L. R. Immunochemical detection of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem. Res. Toxicol. 1993; 6: 147–150, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pumford N. J., Halmes N. C., Hinson J. A. Covalent binding of xenobiotics to specific proteins in the liver. Drug Metab. Rev. 1997; 29: 39–57, [PUBMED], [INFOTRIEVE], [CSA]
- Qui Y., Burlingame A. L., Benet L. Z. Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin: Studies by tandem mass spectrometry. Drug Metab. Dispos. 1998; 26: 246–256, [CSA]
- Rabkin J. M., Smith M. J., Orloff S. L., Corless C. L., Stenzel P., Olyaei A. J. Fatal fulminant hepatitis associated with bromfenac use. Ann. Pharmacother. 1999; 33: 945–947, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ramachandran V., Kostrubsky V. E., Komoroski B. J., Zhang S., Dorko K., Esplen J. E., Strom S. C., Venkataramanan R. Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos. 1999; 27: 1194–1199, [PUBMED], [INFOTRIEVE], [CSA]
- Reid J. M., Kuffel M. J., Miller J. K., Rios R., Ames M. M. Metabolic activation of dacarbazine by human cytochromes P450: The role of CYP1A1, CYP1A2, and CYP2E1. Clin. Cancer Res. 1999; 5: 2192–2197, [PUBMED], [INFOTRIEVE], [CSA]
- Riley R. J., Kitteringham N. R., Park B. K. Structural requirements for bioactivation of anticonvulsants to cytoxic metabolism in vitro. Br. J. Clin. Pharmacol. 1989; 28: 482–487, [PUBMED], [INFOTRIEVE]
- Riska P., Lamson M., Macgregor T., Sabo J., Hattox S., Pav J., Keirns J. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab. Dispos. 1999; 27: 895–901, [PUBMED], [INFOTRIEVE], [CSA]
- Robin M. A., Maratrat M., Le Roy M., Le Breton F. P., Bonierbale E., Dansette P., Ballet F., Mansuy D., Pessayre D. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2C11 and 2C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and ecognized by human sera. J. Clin. Invest. 1996; 98: 1471–1480, [PUBMED], [INFOTRIEVE], [CSA]
- Rodman J. S., Deutsch D. J., Gutman S. I. Methyldopa hepatitis; A report of six cases and review of the literature. Am. J. Med. 1976; 60: 941–948, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Rodriguez R. J., Acosta D., Jr. Comparison of ketoconazole- and fluconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1995; 96: 83–92, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodriguez R. J., Acosta D., Jr. N-deacetyl ketoconazole-induced hepatotoxicity in a primary culture system of rat hepatocytes. Toxicology 1997a; 117: 123–131, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rodriguez R. J., Acosta D., Jr. Metabolism of ketoconazole and deacetylated ketoconazole by rat hepatic microsomes and flavin-containing monooxygenases. Drug Metab. Dispos. 1997b; 25: 772–777, [PUBMED], [INFOTRIEVE], [CSA]
- Roller S. G., Dieckhaus D. M., Santos W. L., Sofia R. D., Macdonald T. L. Interaction between human serum albumin and the felbamate metabolites 4-hydroxy-5-phenyl-[1,3]oxazinan-2-one and 2-phenylpropenal. Chem. Res. Toxicol. 2002; 15: 815–824, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Rosenblum L. E., Korn R. J., Zimmerman H. J. Hepatocellular jaundice as a complication of iproniazid therapy. Arch. Intern. Med. 1960; 105: 583, [PUBMED], [INFOTRIEVE]
- Roth R. A., Luyendyk J. P., Maddox J. F., Ganey P. E. Inflammation and drug idiosyncrasy—is there a connection?. J. Pharmacol. Exp. Ther. 2003; 307: 1–8, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Roy S., Francis F. T., Born C. K., Hamrick M. E. Interaction of dantrolene with the hepatic mixed function oxidase system. Res. Commun. Chem. Pathol. Pharmacol. 1980; 27: 507–520, [PUBMED], [INFOTRIEVE]
- Rozman E., Galceran M. T., Anglada L., Albet C. Investigation of the metabolism of ebrotidine in human urine by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry. Drug Metab. Dispos. 1995; 23: 976–981, [PUBMED], [INFOTRIEVE], [CSA]
- Rwagacondo C. E., Niyitegeka F., Sarushi J., Karema C., Mugisha V., Dujardin J. C., Van Overmeir C., van den Ende J., D'Alessandro U. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am. J. Trop. Med. Hyg. 2003; 68: 743–747, [PUBMED], [INFOTRIEVE], [CSA]
- Sadeque A. J.M., Fisher M. B., Korzekwa K. R., Gonzalez F. J., Rettie A. E. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J. Pharmacol. Exp. Ther. 1997; 283: 698–703, [PUBMED], [INFOTRIEVE], [CSA]
- Sahi J., Hamilton G., Sinz M., Barros S., Huang S. M., Lesko L. J., LeCluyse E. L. Effect of troglitazone on cytochrome P450 enzymes in primary cultures of human and rat hepatocytes. Xenobiotica 2000; 30: 273–284, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Satoh H., Gillette J. R., Davies H. W., Schulick R. D., Pohl L. R. Immunochemical evidence of trifluoroacetylated cytochrome P-450 in the liver of halothane-treated rats. Mol. Pharmacol. 1985; 28: 468–474, [PUBMED], [INFOTRIEVE], [CSA]
- Satoh H., Martin B. M., Schulick A. H., Christ D. D., Kenna J. G., Pohl L. R. Human anti-endoplasmic reticulum antibodies in sera of patients with halothane-induced hepatitis are directed against a trifluoroacetylated carboxylesterase. Proc. Natl. Acad. Sci. USA 1989; 86: 322–326, [PUBMED], [INFOTRIEVE], [CSA]
- Schnyder B., Mauri-Hellweg D., Zanni M., Bettens F., Pichler W. J. Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones. J. Clin. Invest. 1997; 100: 136–141, [PUBMED], [INFOTRIEVE], [CSA]
- Seitz S., Kretz-Rommel A., Oude Elferink R. P., Boelsterli U. A. Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem. Res. Toxicol. 1998; 11: 513–519, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shear N. H., Spielberg S. P., Cannon M., Miller M. Anticonvulsant hypersensitivity syndrome: In vitro risk assessment. J. Clin. Invest. 1988; 82: 1826–1832, [PUBMED], [INFOTRIEVE]
- Shen M. L., Johnson K. L., Mays D. C., Lipsky J. J., Naylor S. Determination of in vivo adducts of disulfiram with mitochondrial aldehyde dehydrogenase. Biochem. Pharmacol. 2001; 61: 537–545, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Shen S., Hatgus S. J., Martin B. M., Pohl L. R. Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Chem. Res. Toxicol. 1997; 10: 420–423, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Simon T., Becquemont L., Mary-Krause M., deWaziers I., Beaune P., Funck-Brentano C., Jaillon P. Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther. 2000; 67: 432–437, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Skibba J. L., Beal D. D., Ramirez G., Bryan G. T. Demethylation of the antineoplastic agent 4(5)-3,3-dimethyl-1-trizeno)-imidazole-5(4)-carboxamide by rats and man. Cancer Res. 1970; 30: 147–150, [PUBMED], [INFOTRIEVE]
- Smith K. S., Smith P. L., Heady T. N., Trugman J. M., Harman W. D., Macdonald T. L. In vitro metabolism of tolcapone to reactive metabolites: Relevance to tolcapone liver toxicity. Chem. Res. Toxicol. 2003; 16: 123–128, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Spaldin V., Madden S., Pool W. F., Park B. K. The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br. J. Clin. Pharmacol. 1994; 38: 15–22, [PUBMED], [INFOTRIEVE], [CSA]
- Spearman M. E., Moloney S. J., Prough R. A. Effect of cytosolic components on the metabolism of the hydrazide iproniazid. Mol. Pharmacol. 1984; 26: 566–573, [PUBMED], [INFOTRIEVE]
- Spracklin D. K., Hankins D. C., Fisher J. M., Thummel K. E., Kharasch E. D. Cytochrome P450 2E1 is the principal catalyst of human oxidative halothane metabolism in vitro. J. Pharmacol. Exp. Ther. 1997; 281: 400–411, [PUBMED], [INFOTRIEVE], [CSA]
- Stewart D. E. Hepatic adverse reactions associated with nefazodone. Can. J. Psychiatry. 2002; 47: 375–377, [PUBMED], [INFOTRIEVE], [CSA]
- Stierlin H., Faigle J. W., Sallmann A., Kung W., Richter W. J., Kriemler H. P., Alt K. O., Winkler T. Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 1979; 9: 601–610, [PUBMED], [INFOTRIEVE]
- Stricker B. H., Blok A. P., Bronkhorst F. B. Glafenine-associated hepatic injury. Analysis of 38 cases and review of the literature. Liver 1986; 6: 63–72, [PUBMED], [INFOTRIEVE]
- Sutton T. S., Koblin D. D., Gruenke L. D., Weiskopf R. B., Rampil I. J., Waskell L., Eger E. I., 2nd. Fluoride metabolites after prolonged exposure of volunteers and patients to desflurane. Anesth. Analg. 1991; 73: 180–185, [PUBMED], [INFOTRIEVE]
- Tang W., Borel A. G., Fujimiya T., Abbott F. S. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: Hepatic microvesicular steatosis and glutathione status. Chem. Res. Toxicol. 1995; 8: 671–682, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tang W., Stearns R. A., Bandiera S. M., Zhang Y., Raab C., Braun M. P., Dean D. C., Pang J., Leung K. H., Doss G. A. Strauss, J.R., Kwei, G.Y., Rushmore, T.H., Chiu, S.L. and Baillie, T.A., Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: Identification of glutathione conjugated metabolites. Drug Metab. Dispos. 1999a; 27: 365–372, [PUBMED], [INFOTRIEVE], [CSA]
- Tang W., Stearns R. A., Wang R. W., Chiu S. L., Baillie T. A. Roles of human hepatic cytochrome P450's 2C9 and 3A4 in the metabolic activation of diclofenac. Chem. Res. Toxicol. 1999b; 12: 192–199, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Tettey J. N., Maggs J. L., Rapeport W. G., Pirmohamed M., Park B. K. Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 2001; 14: 965–974, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thomas J. A. Commentary: “Black box” warning labels and drug withdrawals. Toxicol. Appl. Pharmacol. 2002; 183: 81–82, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thompson C. D., Kinter M. T., Macdonald T. L. Synthesis and in vitro reactivity of 3-carbamoyl-2-phenylpropionaldehyde and 2-phenylpropenal: Putative reactive metabolites of felbamate. Chem. Res. Toxicol. 1996; 9: 1225–1229, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thompson C. D., Gulden P. H., Macdonald T. L. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem. Res. Toxicol. 1997; 10: 457–462, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thompson D. C., Perera K., London R. Quinone methide formation from para isomers of methylphenol (cresol), ethylphenol and isopropylphenol: Relationship to toxicity. Chem. Res. Toxicol. 1995; 8: 55–60, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Thompson D. C., Perera K., London R. Studies on the mechanism of hepatotoxicity of 4-methylphenol (p-cresol): Effects of deuterium labeling and ring substitution. Chem. Biol. Interact. 1996; 101: 1–11, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Timbrell J. A., Mitchell J. R., Snodgrass W. R., Nelson S. Isoniazid hepatotoxicity: The relationship between covalent binding and metabolism in vivo. J. Pharmacol. Exp. Ther. 1980; 213: 364–369, [PUBMED], [INFOTRIEVE]
- Tolman K. G. Hepatotoxicity of non-narcotic analgesics. Am. J. Med. 1998; 105(1B)13S–19S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Toyoda Y., Tsuchida A., Iwami E., Miwa I. Toxic effect of troglitazone on cultured rat hepatocytes. Life Sci. 2001; 68: 1867–1876, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Tukey R. H., Strassburg C. P. Human UDP-glucuronosyltransferases: Metabolism, expression and disease. Annu. Rev. Pharmacol. Toxicol. 2000; 40: 581–616, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Uetrecht J. New concepts in immunology relevant to idiosyncratic drug reactions: The “danger hypothesis” and innate immune system. Chem. Res. Toxicol. 1999; 12: 387–395, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Uetrecht J. Prediction of a new drug's potential to cause idiosyncratic reactions. Curr. Opin. Drug Discov. Develop. 2001; 4: 55–59, [CSA]
- Utili R., Boitnott J. K., Zimmerman H. J. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72: 610–616, [PUBMED], [INFOTRIEVE]
- Van Pelt F. N., Kenna J. G. Formation of trifluoroacetylated protein antigens in cultured rat hepatocytes exposed to halothane in vitro. Biochem. Pharmacol. 1994; 48: 461–471, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vergani D., Mieli-Vergani G., Alberti A., Neuberger J., Eddleston A. L., Davis M., Williams R. Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 1980; 303: 66–71, [PUBMED], [INFOTRIEVE]
- Vickers A. E., Sinclair J. R., Zollinger M., Heitz F., Glanzel U., Johanson L., Fischer V. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 1999; 27: 1029–1038, [PUBMED], [INFOTRIEVE], [CSA]
- Von Greyerz S., Zanni M., Schnyder B., Pichler W. J. Presentation of non-peptide antigens, in particular drugs, to specific T-cells. Clin. Exp Allergy 1998; 28(Suppl. 4)7–11, [PUBMED], [INFOTRIEVE], [CSA]
- Von Moltke L. L. Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: Cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology (Berl). 1999; 145: 113–122, [CROSSREF], [CSA]
- Wakabayashi T., Onda H., Tada T., Iijima M., Itoh Y. High incidence of peliosis hepatitis in autopsy cases of aplastic anemia with special reference to anabolic steroid therapy. Acta Pathol. Jpn. 1984; 34: 1079–1086, [PUBMED], [INFOTRIEVE]
- Weber C., Gasser R., Hopfgartner G. Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects. Drug Metab. Dispos. 1999; 27: 810–815, [PUBMED], [INFOTRIEVE], [CSA]
- Wen X., Wang J-S., Neuvonen P. J., Backman J. T. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes. Eur. J. Clin. Pharmacol. 2002; 7: 799–804, [CROSSREF]
- White I. N. Tamoxifen: Is it safe? Comparison of activation and detoxication mechanisms in rodents and in humans. Curr. Drug Metab. 2003; 4: 223–239, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Wolkenstein P., Tan C., Lecoeur S., Wechsler J., Garcia-Martin N., Charue D., Bagot M., Beaune P. Covalent binding of carbamazepine reactive metabolites to p450 isoforms present in the skin. Chem. Biol. Interact. 1998; 113: 39–50, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Wood A. J. The safety of new medicines. JAMA 1999; 281: 1753–1754, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Woolf T. F., Pool W. F., Bjorge S. M., Chang T., Goel O. P., Purchase C. F., Schroeder M. C., Kunze K. L., Trager W. F. Bioactivation and irreversible binding of the cognition activator tacrine using human and rat liver microsomal preparations: Species difference. Drug Metab. Dispos. 1993; 21: 874–882, [PUBMED], [INFOTRIEVE], [CSA]
- Wright G. J., Zeiger A. V., Leeson G. A., Lang J. F. The absorption, excretion and metabolism of perhexiline maleate by the human. Postgrad. Med. J. 1973; 49: 8–15, [PUBMED], [INFOTRIEVE]
- Wysowski D. K., Fourcroy J. L. Flutamide hepatotoxicity. J. Urol. 1996; 155: 209–212, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamamoto Y., Yamazaki H., Ikeda T., Watanabe T., Iwabuchi H., Nakajima M., Yokoi T. Formation of a novel quinone epoxide metabolite of troglitazone with cytotoxicity to HepG2 cells. Drug Metab. Dispos. 2002; 30: 155–160, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F. P., Yokoi T. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab. Dispos. 1999; 27: 1260–1266, [PUBMED], [INFOTRIEVE], [CSA]
- Yourick J. J., Faiman M. D. Disulfiram metabolism as a requirement for the inhibition of rat liver mitochondrial low Km aldehyde dehydrogenase. Biochem. Pharmacol. 1991; 42: 1361–1366, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zanni M. P., Schnyder B., von Greyerz S., Pichler W. J. Involvement of T cells in drug-induced allergies. Trends Pharmacol. Sci. 1998; 19: 308–310, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Zein N., Sinha A. M., McGahren W. J., Ellestad G. A. Calicheamicin gamma 1I: An antitumor antibiotic that cleaves double stranded DNA site specifically. Science 1988; 240: 1198–1201, [PUBMED], [INFOTRIEVE]
- Zein N., Poncin M., Nilakantan R., Ellestad G. A. Calicheamicin gamma 1I and DNA: Molecular recognition process responsible for site-specificity. Science 1989; 244: 697–699, [PUBMED], [INFOTRIEVE]
- Zimmerman H. J. Hepatotoxicity. The adverse effect of drugs and other chemicals on the liver2nd ed. Williams & Wilkins, Philadelphia 1999, Lippincott
- Zimmerman H. J., Lewis J. H., Ishak K. G., Maddrey W. C. Ticrynafen-associated hepatic injury: Analysis of 340 cases. Hepatology 1984; 4: 315–323, [PUBMED], [INFOTRIEVE]
- Zimmerman L. J., Valentine H. S., Amarnath K., Valentine W. M. Identification of a S-hexahydro-1H-azepine-1-carbonyl adduct produced by molinate on rat hemoglobin β2 and β3 chains in vivo. Chem. Res. Toxicol. 2002; 15: 209–217, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]